Preservative-free Tafluprost Eye Drops in Newly Diagnosed Patients With Glaucoma
- Registration Number
- NCT04455126
- Lead Sponsor
- Alexandria University
- Brief Summary
Glaucoma encompasses a collective group of optic neuropathies characterized by progressive degeneration of retinal ganglion cells and their axons, resulting in cupping, a distinctive appearance of the optic disc, and a pattern of visual loss
- Detailed Description
Saflutan® is the first preservative-free prostaglandin analog introduced to the Egyptian market. It contains the PG analog tafluprost. Better tolerability, higher adherence to treatment and improvement of patients' quality of life are associated with using preservative-free eye drops.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Adult males and females, newly diagnosed with glaucoma, naïve to glaucoma medications and surgery, able to read, comprehend, and complete the Ocular Surface Disease Index (OSDI) questionnaire, and able to provide informed consent form.
Exclusion Criteria
- Unable to provide informed consent form
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Preservative-free tafluprost Preservative-free tafluprost eye drops This was an open-label, non-randomized clinical study that aimed to assess the ocular signs and symptoms in 60 eyes of 30 newly diagnosed Egyptian glaucoma patients receiving preservative-free tafluprost eye drops
- Primary Outcome Measures
Name Time Method Intraocular pressure (IOP) 12 weeks Intraocular pressure (IOP)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Alexandria Faculty of Medicine
🇪🇬Alexandria, Egypt